Top

Annals of Hematology

Published in:

01-06-2013 | Letter to the Editor

Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation

Authors: Ryan Carr, Spero R. Cataland

Published in: Annals of Hematology | Issue 6/2013

Excerpt

Dear Editor, …

Noris M, Remuzzi G (2009) Atypical hemolytic–uremic syndrome. N Engl J Med 361(17):1676–1687. doi:10.1056/NEJMra0902814 PubMedCrossRef

Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233–1243. doi:10.1056/NEJMoa061648 PubMedCrossRef

Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117(25):6786–6792. doi:10.1182/blood-2011-02-333997 PubMedCrossRef

Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26(4):613–619. doi:10.1007/s00467-010-1708-6 PubMedCrossRef

Chatelet V, Lobbedez T, Fremeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 42(10):4353–4355. doi:10.1016/j.transproceed.2010.09.125 PubMedCrossRef

Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic–uremic syndrome. N Engl J Med 360(5):544–546. doi:10.1056/NEJMc0809959 PubMedCrossRef

Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P (2011) Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 26(4):621–624. doi:10.1007/s00467-010-1719-3 PubMedCrossRef

Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4(8):1312–1316. doi:10.2215/CJN.01090209 PubMedCrossRef

Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360(5):542–544. doi:10.1056/NEJMc0808527 PubMedCrossRef

10.

Prescott HC, Wu HM, Cataland SR, Baiocchi RA (2010) Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol 85(12):976–977. doi:10.1002/ajh.21862 PubMedCrossRef

11.

Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7(1):23–35. doi:10.1038/nrneph.2010.155 PubMedCrossRef

Title: Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation
Authors: Ryan Carr
Spero R. Cataland
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 6/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-012-1622-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2013

Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East

Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany

Hodgkin’s lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study

Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page